Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Gastroenterology. 2023 Mar 31;165(1):149–161.e7. doi: 10.1053/j.gastro.2023.03.224

Table 3.

Differences in PROMIS Pain Interference and Fatigue between Combination Therapy and Monotherapy Groups

Overall Pain Interference Fatigue
Effect estimate p Effect estimate p
Week 52 −1.36 0.33 0.59 0.64
Week 104 −0.70 0.69 0.88 0.64
Infliximab
Week 52 −1.29 0.43 0.52 0.79
Week 104 −1.40 0.52 0.05 0.98
Adalimumab
Week 52 −1.56 0.55 0.82 0.79
Week 104 0.81 0.78 2.93 0.34

Effect estimate is mean difference in T scores between the active and placebo groups. Negative values indicate lower levels of the measured domain in active versus placebo groups. Minimally important differences in PROMIS measures are in the range of 3–5 based on studies in other populations.